WTAM Local News

 

Cleveland Clinic study targets prostate cancer

Cleveland Clinic study targets prostate cancer

(Cleveland) - Researchers may now be on the road to stopping prostate cancer in its tracks. They’ve identified the way certain tumors become resistant to prostate cancer medications.

Dr. Nima Sharifi led this newest study at Cleveland Clinic.

“We’ve really identified a critical mechanism of resistance to standard treatment of prostate cancer and that this is a critical, but first step in terms of developing better treatments,” says Dr. Sharifi.

Dr. Sharifi says prostate cancer needs androgen to grow. It fuels the tumor. So, prostate cancer is typically treated by using medications which stop the production of androgen and starves the tumor.

But certain tumors resist medication and develop the ability to make androgen on its own and continue growing…until now.

Dr. Sharifi and his team of researchers discovered what causes a tumor to develop its own androgen, or essentially make its own fuel.

“We have some understanding of how these tumors become resistant and synthesize their own fuel, but no one has ever really described a mutation that’s responsible for performing this function.”

Dr. Sharifi hopes this allows for the development of a drug that can stop the tumor from creating its own androgen. He says the other aspect of this is this actually provides for a potential drug target for the development of new treatments.”

Dr. Sharifi is hopeful the findings may be used to stop other types of cancer as well. Complete findings for this study are in the journal “Cell.”

 Get breaking news sent to your mobile phone. Text "news" to 21095.

(Copyright © 2013 by Clear Channel, all rights reserved.)

 

More Articles